500 related articles for article (PubMed ID: 12426403)
1. The mechanism of topoisomerase I poisoning by a camptothecin analog.
Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403
[TBL] [Abstract][Full Text] [Related]
2. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
4. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
5. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
6. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.
Marco E; Laine W; Tardy C; Lansiaux A; Iwao M; Ishibashi F; Bailly C; Gago F
J Med Chem; 2005 Jun; 48(11):3796-807. PubMed ID: 15916431
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
Pommier Y; Pourquier P; Fan Y; Strumberg D
Biochim Biophys Acta; 1998 Oct; 1400(1-3):83-105. PubMed ID: 9748515
[TBL] [Abstract][Full Text] [Related]
9. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
Losasso C; Cretaio E; Fiorani P; D'Annessa I; Chillemi G; Benedetti P
Nucleic Acids Res; 2008 Oct; 36(17):5635-44. PubMed ID: 18772225
[TBL] [Abstract][Full Text] [Related]
10. Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence.
Koster DA; Czerwinski F; Halby L; Crut A; Vekhoff P; Palle K; Arimondo PB; Dekker NH
Nucleic Acids Res; 2008 Apr; 36(7):2301-10. PubMed ID: 18292117
[TBL] [Abstract][Full Text] [Related]
11. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
12. Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone.
Mulholland K; Wu C
J Chem Inf Model; 2016 Sep; 56(9):1872-83. PubMed ID: 27564845
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase I poisons.
Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
[No Abstract] [Full Text] [Related]
14. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
15. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.
Li XG; Haluska P; Hsiang YH; Bharti A; Kufe DW; Rubin EH
Ann N Y Acad Sci; 1996 Dec; 803():111-27. PubMed ID: 8993505
[No Abstract] [Full Text] [Related]
16. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
Mancini G; D'Annessa I; Coletta A; Sanna N; Chillemi G; Desideri A
PLoS One; 2010 Jun; 5(6):e10934. PubMed ID: 20532182
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
[TBL] [Abstract][Full Text] [Related]
18. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Pourquier P; Pommier Y
Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
20. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
